Effects of Torcetrapib in Patients at High Risk for Coronary Events
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inhibition of cholesteryl ester transfer protein (CETP) has been shown to have a substantial effect on plasma lipoprotein levels. We investigated whether torcetrapib, a potent CETP inhibitor, might reduce major cardiovascular events. The trial was terminated prematurely because of an increased risk of death and cardiac events in patients receiving torcetrapib. METHODS: We conducted a randomized, double-blind study involving 15,067 patients at high cardiovascular risk. The patients received either torcetrapib plus atorvastatin or atorvastatin alone. The primary outcome was the time to the first major cardiovascular event, which was defined as death from coronary heart disease, nonfatal myocardial infarction, stroke, or hospitalization for unstable angina. RESULTS: At 12 months in patients who received torcetrapib, there was an increase of 72.1% in high-density lipoprotein cholesterol and a decrease of 24.9% in low-density lipoprotein cholesterol, as compared with baseline (P<0.001 for both comparisons), in addition to an increase of 5.4 mm Hg in systolic blood pressure, a decrease in serum potassium, and increases in serum sodium, bicarbonate, and aldosterone (P<0.001 for all comparisons). There was also an increased risk of cardiovascular events (hazard ratio, 1.25; 95% confidence interval [CI], 1.09 to 1.44; P=0.001) and death from any cause (hazard ratio, 1.58; 95% CI, 1.14 to 2.19; P=0.006). Post hoc analyses showed an increased risk of death in patients treated with torcetrapib whose reduction in potassium or increase in bicarbonate was greater than the median change. CONCLUSIONS: Torcetrapib therapy resulted in an increased risk of mortality and morbidity of unknown mechanism. Although there was evidence of an off-target effect of torcetrapib, we cannot rule out adverse effects related to CETP inhibition. (ClinicalTrials.gov number, NCT00134264 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, BIA 10-2474 (Section 7.3) and torcetrapib (Section 7.5) are off-target toxicities that surfaced only at clinical exposures.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor designed to raise HDL-cholesterol, produced favourable surrogate-biomarker changes in trials but increased all-cause mortality in the ILLUMINATE outcome study.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“The mortality signal traced not to CETP inhibition itself but to off-target hemodynamic effects, including aldosterone elevation, blood pressure increases, and electrolyte shifts independent of the lipid mechanism [25].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [25]
In the citing paper
“three large RCTs of cholesterol ester transfer protein inhibitors (dalcetrapib, evacetrapib, and torcetrapib) did not improve CV outcomes despite substantial increases in plasma HDL-C levels”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [20]
In the citing paper
“Furthermore, phase 3 trials of cholesteryl ester transfer protein inhibitors have shown that reducing LDL-C does not necessarily prevent CVD.”
From Saturated Fat Restriction for Cardiovascular Disease Prevention: A Systematic Review and Meta-analysis of Randomized Controlled Trials (2025) · cites this paper as [8]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies.
Gordon, D. J., Probstfield, J. L., Garrison, R. J., Neaton, J. D., Castelli, W. P., Knoke, J. D., Jacobs, D. R., Bangdiwala, S., & Tyroler, H. A. (1989) · Circulation · doi:10.1161/01.cir.79.1.8 · Cited by 3,162
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Self-citationEffect of Torcetrapib on the Progression of Coronary Atherosclerosis
Nissen, S. E., Tardif, J.-C., Nicholls, S. J., Revkin, J. H., Shear, C. L., Duggan, W. T., Ruzyllo, W., Bachinsky, W. B., Lasala, G. P., & Tuzcu, E. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070635 · Cited by 966
Self-citationCholesteryl Ester Transfer Protein: A Novel Target for Raising HDL and Inhibiting Atherosclerosis
Barter, P. J., Brewer, H. B., Chapman, M. J., Hennekens, C. H., Rader, D. J., & Tall, A. R. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000054658.91146.64 · Cited by 870
Self-citationEffects of an Inhibitor of Cholesteryl Ester Transfer Protein on HDL Cholesterol
Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., Bloedon, L. T., Digenio, A. G., Clark, R. W., Mancuso, J. P., & Rader, D. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa031766 · Cited by 774
Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia
Kastelein, J. J. P., van Leuven, S. I., Burgess, L., Evans, G. W., Kuivenhoven, J. A., Barter, P. J., Revkin, J. H., Grobbee, D. E., Riley, W. A., Shear, C. L., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071359 · Cited by 658
Self-citationHDL as a target in the treatment of atherosclerotic cardiovascular disease
Linsel-Nitschke, P., & Tall, A. R. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1658 · Cited by 486
Self-citationHigh-Density Lipoprotein as a Therapeutic Target: A Systematic Review
Singh, I. M., Shishehbor, M. H., & Ansell, B. J. (2007) · JAMA · doi:10.1001/jama.298.7.786 · Cited by 468
Bots, M. L., Visseren, F. L., Evans, G. W., Riley, W. A., Revkin, J. H., Tegeler, C. H., Shear, C. L., Duggan, W. T., Vicari, R. M., Grobbee, D. E., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61088-5 · Cited by 461
Self-citation
Cited by
Items 801–900 of 1,017
Chandra, A., Neeland, I. J., Das, S. R., Khera, A., Turer, A. T., Ayers, C. R., McGuire, D. K., & Rohatgi, A. K. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2015.01.015 · Cited by 47
Erbel, R. M., Lehmann, N., Churzidse, S., Möhlenkamp, S., Moebus, S., Mahabadi, A. A., Schmermund, A., Stang, A., Dragano, N., Grönemeyer, D. H. W., et al. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.04.015 · Cited by 44
“These results may help to explain, why HDL-C, as it is analysed today, without checking for subunits or functional differentiation, can only be regarded as a marker of risk, but failed to show any benefit, even adverse outcome, when measures were undertaken to increase the HDL-C concentration [38].”
ResultPCSK9 inhibition: the way forward in the treatment of dyslipidemia
Stoekenbroek, R. M., Kastelein, J. J., & Huijgen, R. (2015) · BMC Medicine · doi:10.1186/s12916-015-0503-4 · Cited by 44
Self-citationEarly diagnosis and treatment of familial hypercholesterolemia: improving patient outcomes
Alonso, R., Mata, P., Zambón, D., Mata, N., & Fuentes, F. J. (2013) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.13.7 · Cited by 44
Leoligin, the major lignan from Edelweiss, activates cholesteryl ester transfer protein
Duwensee, K., Schwaiger, S., Tancevski, I., Eller, K., Eck, M. V., Markt, P., Linder, T., Stanzl, U., Ritsch, A., Patsch, J. R., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.023 · Cited by 46
“torcetrapib was disrupted prior to schedule because of an excess of cardiovascular and overall mortality in the active treatment group [7].”
BackgroundWeight loss surgery in adolescents corrects high-density lipoprotein subspecies and their function
Davidson, W. S., Inge, T. H., Sexmith, H., Heink, A., Elder, D., Hui, D. Y., Melchior, J. T., Kelesidis, T., & Shah, A. S. (2017) · International Journal of Obesity · doi:10.1038/ijo.2016.190 · Cited by 43
Lipid Metabolism and Emerging Targets for Lipid-Lowering Therapy
Gaudet, D., Drouin‐Chartier, J., & Couture, P. (2017) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.12.019 · Cited by 46
The Genetic Architecture of Coronary Artery Disease: Current Knowledge and Future Opportunities
Hartiala, J., Schwartzman, W. S., Gabbay, J., Ghazalpour, A., Bennett, B. J., & Allayee, H. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0641-6 · Cited by 47
When less is more – efficacy with less toxicity at the ED50
Dimmitt, S. B., Stampfer, H. G., & Martin, J. H. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13281 · Cited by 46
Nicholls, S. J., Ray, K. K., Ballantyne, C. M., Beacham, L. A., Miller, D. L., Ruotolo, G., Nissen, S. E., & Riesmeyer, J. S. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.04.008 · Cited by 44
Karalis, I. K., & Jukema, J. W. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1004-9 · Cited by 47
Li, X., Guan, B., Wang, Y., Tse, G., Zou, F., Waleed, K. B., Xia, Y., Wu, S., & Sun, J. (2019) · Scientific Reports · doi:10.1038/s41598-019-50924-4 · Cited by 49
2-Arylbenzoxazoles as CETP inhibitors: Substitution of the benzoxazole moiety
Smith, C. J., Ali, A., Chen, L., Hammond, M. L., Anderson, M. S., Chen, Y., Eveland, S. S., Guo, Q., Hyland, S. A., Milot, D. P., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.099 · Cited by 47
Importancia del colesterol HDL en la aterotrombosis. ¿De dónde venimos? ¿Hacia dónde vamos?
Badimón, J. J., Santos‐Gallego, C. G., & Badimón, L. (2010) · Revista Española de Cardiología · doi:10.1016/s0300-8932(10)70150-0 · Cited by 58
Muth, N. D., Laughlin, G. A., von Mühlen, D. G., Smith, S. C., & Barrett-Connor, E. L. (2010) · British Journal Of Nutrition · doi:10.1017/s0007114510001595 · Cited by 42
Surrogate End Points and FDA Approval
Psaty, B. M., & Lumley, T. (2008) · JAMA · doi:10.1001/jama.299.12.1474 · Cited by 43
The effect of CETP inhibitors on new-onset diabetes: a systematic review and meta-analysis
Dangas, K., Navar, A.-M., & Kastelein, J. J. P. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac025 · Cited by 48
Self-citationNavar, A. M., Fine, L. J., Ambrosius, W. T., Brown, A., Douglas, P. S., Johnson, K., Khera, A. V., Lloyd-Jones, D., Michos, E. D., Mujahid, M., et al. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100430 · Cited by 43
“High density lipoprotein cholesterol (HDL-C) is an example of a surrogate that is correlated with cardiovascular events, but changing HDL-C with niacin or CETP inhibitors did not impact cardiovascular events [73,74].”
BackgroundPoliakova, T., & Wellington, C. L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00671-y · Cited by 48
“Torce-trapib inhibited the development of atherosclerosis in rabbits and, in early-phase studies in humans, increased HDL-C by 60 to 100% and lowered LDL-C by up to 20% [158].”
BackgroundeNOS Activation by HDL Is Impaired in Genetic CETP Deficiency
Gomaraschi, M., Ossoli, A., Pozzi, S., Nilsson, P., Cefalu, A. B., Averna, M. R., Kuivenhoven, J. A., Hovingh, G. K., Veglia, F., Franceschini, G., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0095925 · Cited by 42
“These unexpected results have been ascribed to either off-target effects of the drug [5,7,8], to weak CETP inhibition and HDL-C raising activity [6], or to mechanism-related effects [9].”
BackgroundParra, S., Vives, G., Ferré, R., González, M., Guardiola, M., Ribalta, J., & Castro, A. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.08.029 · Cited by 42
New Therapies for Reducing Low-Density Lipoprotein Cholesterol
Stein, E. A., & Raal, F. J. (2014) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2014.08.008 · Cited by 42
Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia
Hermann, F., Enseleit, F., Spieker, L. E., Périat, D., Sudano, I., Hermann, M., Corti, R., Noll, G., Ruschitzka, F. T., & Lüscher, T. F. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.06.022 · Cited by 42
“In the ILLUMINATE trial, however, the CETP inhibitor torcetrapib increased the rate of cardiovascular and non-cardiovascular events, an increase in HDL cholesterol of 72.1% and a decrease in LDL cholesterol of 24.9% notwithstanding [ 9 ].”
BackgroundResultInfluentialKurogi, K., Sugiyama, S., Sakamoto, K., Tayama, S., Nakamura, S., Biwa, T., Matsui, K., & Ogawa, H. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.03.008 · Cited by 42
Singh, S. A., Andraski, A. B., Pieper, B., Goh, W., Mendivil, C. O., Sacks, F. M., & Aikawa, M. (2016) · Journal of Lipid Research · doi:10.1194/jlr.d061432 · Cited by 42
Comparison of Preventive Effect on Cardiovascular Events With Different Statins - The CIRCLE Study -
Maruyama, T., Takada, M., Nishibori, Y., Fujita, K., Miki, K., Masuda, S., Horimatsu, T., & Hasuike, T. (2011) · Circulation Journal · doi:10.1253/circj.cj-10-1163 · Cited by 42
Qin, Y., Ran, L., Wang, J., Yu, L., Lang, H., Wang, X., Mi, M., & Zhu, J. (2017) · Nutrients · doi:10.3390/nu9091037 · Cited by 49
“To put this into perspective, it has been reported that every 1-mg/dL increment in HDL-C levels is related to reductions of 2–3% in CVD risk [24].”
BackgroundInfluentialFavari, E., Thomas, M. J., & Sorci‐Thomas, M. G. (2018) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000573 · Cited by 47
Tofte, N., Vogelzangs, N., Mook-Kanamori, D. O., Brahimaj, A., Nano, J., Ahmadizar, F., van Dijk, K. W., Frimodt‐Møller, M., Arts, I. C. W., Beulens, J. W. J., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa173 · Cited by 41
“Targeting HDL cholesterol or phospholipids may be a future therapeutic approach, although previous clinical studies with HDL cholesterol increasing agents—for example, torcetrapib (42) in high-risk individuals of cardiovascular disease— have demonstrated increased risk of mortality and morbidity of unknown mechanism.”
ResultAlbuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View
Fried, L. F., & Lewis, J. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10681014 · Cited by 42
Cartolano, F. D. C., Dias, G. D. F., Miyamoto, S., & Damasceno, N. R. T. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2021.767535 · Cited by 48
“These investigations are particularly attractive due to the successive unsuccess observed in clinical trials based on drugs focused on the cardioprotective role of HDL (21, 22).”
BackgroundHigh-Density Lipoproteins: A Role in Inflammation in COPD
Kotlyarov, S. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158128 · Cited by 46
“Attention to the role of CETP in immune response has increased because of the large number of infection-related deaths in the ILLUMINATE trial in which the CETP inhibitor torcetrapib was studied [219,220].”
BackgroundEnhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels
Hausenloy, D. J., & Yellon, D. M. (2009) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32832ebfe7 · Cited by 46
Clinical trials in stem cell transplantation: guidelines for scientific and ethical review
Lo, B., Kriegstein, A. R., & Grady, D. G. (2008) · Clinical Trials · doi:10.1177/1740774508096705 · Cited by 41
“drug torcetrapib improved the surrogate endpoints of HDL and LDL levels when added to standard statin therapy, but increased total mortality [22].”
BackgroundHanai, K., Babazono, T., Yoshida, N., Nyumura, I., Toya, K., Hayashi, T., Bouchi, R., Tanaka, N., Ishii, A., & Iwamoto, Y. (2011) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfr417 · Cited by 46
Ooi, E. M. M., Afzal, S., & Nordestgaard, B. G. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.113.000416 · Cited by 44
The metabolic vascular syndrome - guide to an individualized treatment
Hanefeld, M., Pistrosch, F., Bornstein, S. R., & Birkenfeld, A. L. (2016) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-016-9345-4 · Cited by 50
“The concept to increase HDL-cholesterol to protect the vessel wall was not supported by recently stopped trials with nicotinic acid [95] and CETP inhibitors [96, 97] showing increased rates of serious adverse events.”
BackgroundVenancio, T. M., Machado, R. M., Castoldi, A., Amano, M. T., Nunes, V. S., Quintao, E. C. R., Camara, N. O. S., Soriano, F. G., & Cazita, P. M. (2016) · Mediators of Inflammation · doi:10.1155/2016/1784014 · Cited by 41
Ajala, O. N., Demler, O., Liu, Y., Farukhi, Z. M., Adelman, S. J., Collins, H. L., Ridker, P. M., Rader, D. J., Glynn, R. J., & Mora, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016507 · Cited by 44
An update on testosterone, HDL and cardiovascular risk in men
Thirumalai, A., Rubinow, K. B., & Page, S. T. (2015) · Clinical Lipidology · doi:10.2217/clp.15.10 · Cited by 47
Zheng, C., & Aikawa, M. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.999 · Cited by 44
“Phase III trials with torcetrapib and dalcetrapib, a class of drugs that elevate the concentration of large, mature HDL through cholesteryl ester transfer protein (CETP) inhibition, were terminated prematurely due to excess adverse events (7) and futility (8).”
BackgroundHuman Genomics and Drug Development
Schmidt, A. F., Hingorani, A. D., & Finan, C. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a039230 · Cited by 41
Treatment of dyslipidemia in diabetes: recent advances and remaining questions
Chait, A., & Goldberg, I. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0942-8 · Cited by 40
Wu, Z., Lou, Y., Qiu, X., Liu, Y., Lu, L., Chen, Q., & Jin, W. (2014) · BMC Medical Genetics · doi:10.1186/s12881-014-0118-1 · Cited by 40
HDL-Cholesterol and Triglycerides Dynamics: Essential Players in Metabolic Syndrome
Alcover, S., Ramos-Regalado, L., Girón, G., Muñoz‐García, N., & Vilahur, G. (2025) · Antioxidants · doi:10.3390/antiox14040434 · Cited by 57
The Role of Early LDL Lowering to Prevent the Onset of Atherosclerotic Disease
Ference, B. A., & Mahajan, N. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0312-1 · Cited by 45
Taylor, A. J., Villines, T. C., & Stanek, E. J. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs105 · Cited by 40
“Could the extent to which ezetimibe inhibits SRB1-related cholesterol absorption,(28) reflected in the measurable extent of LDL-C reduction, be more than offset by an unmeasurable ezetimibe-induced inhibition of other transport mechanisms known to be important in HDL-related reverse cholesterol transport? Which other…”
BackgroundHigh-density lipoproteins and cardiovascular disease: 2010 update
Al-Waili, K., Awan, Z. A., Alshahrani, A., & Genest, J. J. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.4 · Cited by 45
Structural Insights into High Density Lipoprotein: Old Models and New Facts
Gogonea, V. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00318 · Cited by 44
“For example, torcetrapib was found to have high toxicity (Barter et al., 2007), however its use in patients treated with atorvastatin enhances cholesterol efflux along pathways involving the SCARB1 and ABCG1 receptors (Catalano et al., 2009).”
BackgroundKoekemoer, A. L., Codd, V., Masca, N. G. D., Nelson, C. P., Musameh, M. D., Kaess, B. M., Hengstenberg, C., Rader, D. J., & Samani, N. J. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309201 · Cited by 40
Genga, K. R., Trinder, M., Kong, H. J., Li, X., Leung, A. K. K., Shimada, T., Walley, K. R., Russell, J. A., Francis, G. A., Brunham, L. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-35261-2 · Cited by 43
Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL
Hui, N., Barter, P. J., Ong, K. L., & Rye, K. (2019) · Clinical Science · doi:10.1042/cs20190873 · Cited by 46
Self-citationA Novel Role for CETP as Immunological Gatekeeper: Raising HDL to Cure Sepsis?
Blauw, L. L., Wang, Y., van Dijk, K. W., & Rensen, P. C. N. (2020) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2020.01.003 · Cited by 44
Wang, M., Liu, M., Li, F., Guo, C., Liu, Z., Pan, Y., Liu, Y., Liu, F., Cai, H., Wu, Y., et al. (2020) · Lipids in Health and Disease · doi:10.1186/s12944-020-01313-8 · Cited by 49
HDL cholesterol levels and susceptibility to COVID-19
Chidambaram, V., Kumar, A., Majella, M. G., Seth, B., Sivakumar, R. K., Voruganti, D. C., Bavineni, M., Baghal, A., Gates, K., Kumari, A., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104166 · Cited by 42
“31 Though some studies on HDL-C-raising agents, such as torcetrapib, reported a non-significant increase in the risk of infectious diseases in the CETP inhibitor arm, 43 this was not observed in other trials with CETP inhibitors.”
Wang, A., Prouty, C. P., Pelton, P. D., Yong, M., Demarest, K. T., Murray, W. V., & Kuo, G. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.12.096 · Cited by 43
Williams, K. J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.320065 · Cited by 47
Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management
Agnello, F., Ingala, S., Laterra, G., Scalia, L., & Barbanti, M. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13051251 · Cited by 39
“In fact, the phase III trial of torcetrapib, the first CETP inhibitor, was disappointing, showing an increased risk of death [76–78].”
BackgroundHigh-density lipoprotein/apolipoprotein A-I infusion therapy
Tardif, J., Heinonen, T. M., & Noble, S. (2008) · Current Atherosclerosis Reports · doi:10.1007/s11883-009-0009-7 · Cited by 39
“With the advent of effective strategies for reducing low-density lipoprotein cholesterol (LDL-C) and triglycerides, it is possible to decrease an individual’s risk for cardiovascular disease, alleviating the burden that cardiovascular disease places on society [1, 2 ].”
BackgroundSelf-citationKhera, A. V., Wolfe, M. L., Cannon, C. P., Qin, J., & Rader, D. J. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.03.057 · Cited by 40
Kuo, G., Rano, T. A., Pelton, P. D., Demarest, K. T., Gibbs, A. C., Murray, W. V., Damiano, B. P., & Connelly, M. A. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801319d · Cited by 39
Dalcetrapib: a review of Phase II data
Robinson, J. G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.488219 · Cited by 38
“Based on the torcetrapib experience of excess mortality after an average 1 year of treatment [30], results of the large, cardiovascular end point trial dal-OUTCOMES will be needed before dalcetrapib receives regulatory approval.”
BackgroundRosuvastatin: efficacy, safety and clinical effectiveness
Soran, H., & Durrington, P. N. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.12.2145 · Cited by 40
“Following the failure of the CETP inhibitor, torcetrapib, to prevent cardiovascular events [142] a reevaluation of the notion that raising HDL-C regardless of the mechanism is beneficial is underway.”
BackgroundDrug Therapy of Hypercholesterolaemia in Children and Adolescents
Braamskamp, M. J. A. M., Wijburg, F. A., & Wiegman, A. (2012) · Drugs · doi:10.2165/11632810-000000000-00000 · Cited by 48
“Torcetrapib was the first CETP inhibitor extensively studied in humans, but the trial was prematurely terminated because of an increased risk ofmortality andmorbidity.([96]) Anacetrapib and dalcetrapib, two other CETP inhibitors, are in phase III development and, although they have been proven effective lipid-lowering…”
BackgroundReyes‐Soffer, G., Millar, J. S., Ngai, C. I., Jumes, P. A., Coromilas, E. J., Asztalos, B. F., Johnson‐Levonas, A. O., Wagner, J. A., Donovan, D. S., Karmally, W., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306680 · Cited by 39
Farràs, M., Fernández‐Castillejo, S., Rubió, L., Arranz, S., Catalán, Ú., Subirana, I., Romero, M.-P., Castañer, O., Pedret, A., Blanchart, G., et al. (2017) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2017.09.010 · Cited by 44
Wacker, B. K., Dronadula, N., Bi, L., Stamatikos, A., & Dichek, D. A. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309565 · Cited by 42
Metabolic Effects of Testosterone Therapy in Men with Type 2 Diabetes and Metabolic Syndrome
Hackett, G. I. (2019) · Sexual Medicine Reviews · doi:10.1016/j.sxmr.2018.12.004 · Cited by 40
Lymphatic system identification, pathophysiology and therapy in the cardiovascular diseases
Hu, D. M., Li, L., Li, S., Wu, M., Ge, N., Cui, Y., Lian, Z., Song, J., & Chen, H. (2019) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2019.06.002 · Cited by 47
Streja, E., Kovesdy, C. P., Streja, D. A., Moradi, H., Kalantar‐Zadeh, K., & Kashyap, M. L. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.11.033 · Cited by 39
Ewang-Emukowhate, M., & Wierzbicki, A. S. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413492906 · Cited by 46
Palmisano, B. T., Le, T. D. V., Zhu, L., Lee, Y., & Stafford, J. M. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m069013 · Cited by 41
“Although two clinical trials of CETP inhibitors did not reduce cardiovascular disease outcomes (12, 13), and a third was recently halted due to inefficacy, CETP inhibition may ultimately remain a viable therapeutic strategy because of its LDL-lowering properties.”
Backgroundvan Capelleveen, J. C., Kastelein, J. J. P., Zwinderman, A. H., van Deventer, S. J. H., Collins, H. L., Adelman, S. J., Round, P., Ford, J., Rader, D. J., & Hovingh, G. K. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.06.006 · Cited by 42
“Indeed, CETP inhibitors were shown to increase HDL-C and apoA-1 levels, but the effect size of the different CETP inhibitors on these parameters varies greatly.(3,4,13,14) To date, however, CVD outcome studies investigating the effect of HDL-C raising modalities on CVD events have failed to show a beneficial effect.”
BackgroundSelf-citationTuñón, J., Fernández‐Fernández, B., Carda, R., Pello, A. M., Cristóbal, C., Tarín, N., Aceña, Á., González‐Casaus, M. L., Huelmos, A. I., Alonso, J. J., et al. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2787 · Cited by 42
“In this regard, drugs that enhance HDL plasma levels failed to improve the prognosis or were even harmful for the patients [37].”
The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis
Yu, M., Tsai, S., & Kuo, Y. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061260 · Cited by 39
“n-3 fatty acids (eicosapentaenoic acid and docosahexaenoic acid) Lower triglyceride levels up to 45% [206]; no significant effect ofω-3 fatty acids on composite CVD events [207] Phase III”
BackgroundMørland, J. G., Magnus, P. M., Vollset, S. E., Leon, D. A., Selmer, R. M., & Tverdal, A. (2023) · International Journal of Epidemiology · doi:10.1093/ije/dyad011 · Cited by 45
Impact of Obicetrapib on Major Adverse Cardiovascular Events in High-Risk Patients
Nicholls, S. J., Nelson, A. J., Ray, K. K., Ballantyne, C. M., Ditmarsch, M., Kling, D. F., Hsieh, A., Szarek, M. J., Kastelein, J. J. P., & Davidson, M. H. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.07.056 · Cited by 44
Self-citationIs niacin ineffective? Or did AIM-HIGH miss its target?
Nicholls, S. J. (2012) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.79a.11166 · Cited by 38
Update on Lipoprotein(a) as a Cardiovascular Risk Factor and Mediator
Boffa, M. B., & Koschinsky, M. L. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0360-6 · Cited by 42
High-density lipoprotein subfractions and carotid plaque: The Northern Manhattan Study
Tiozzo, E., Gardener, H. E., Hudson, B. I., Dong, C., Della‐Morte, D., Crisby, M., Goldberg, R. B., Elkind, M. S. V., Cheung, Y. K., Wright, C. B., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.09.002 · Cited by 42
Cholesteryl ester transfer protein and its inhibition
Weber, O., Bischoff, H., Schmeck, C., & Böttcher, M.-F. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0418-3 · Cited by 38
“HDL increase and LDL decrease have also been observed in large phase III studies [33‐36]: the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) study [ 33 ], the Investigation of Lipid Level Management Using Coronary Ultrasound (ILLUSTRATE) study [34] and the Ratin…”
BackgroundResultCilostazol enhances macrophage reverse cholesterol transport in vitro and in vivo
Nakaya, K., Ayaori, M., Uto‐Kondo, H., Hisada, T., Ogura, M., Yakushiji, E., Takiguchi, S., Terao, Y., Ozasa, H., Sasaki, M., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.07.024 · Cited by 39
Halcox, J., & Misra, A. (2014) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2014.0049 · Cited by 45
Girona, J., Ibarretxe, D., Plana, N., Guaita‐Esteruelas, S., Amigó, N., Heras, M., & Masana, L. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0428-z · Cited by 41
“Inhibiting CETP decreases the concentration of LDL-C by up to 45 % and increases the concentration of HDL-C by up to 180 % [11–14].”
BackgroundTemporal Trends and Factors Associated With Cardiovascular Drug Development, 1990 to 2012
Hwang, T. J., Lauffenburger, J. C., Franklin, J. M., & Kesselheim, A. S. (2016) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2016.03.012 · Cited by 42
“Torcetrapib (23) Prevention of cardiovascular disease (Pfizer) Randomized, double-blind Atorvastatin Time to first major cardiovascular event† Halted due to safety concerns (increased risk of death and cardiovascular events)”
BackgroundMendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
Blauw, L. L., Noordam, R., Soidinsalo, S., Blauw, C. A., Li‐Gao, R., de Mutsert, R., Berbée, J. F. P., Wang, Y., van Heemst, D., Rosendaal, F. R., et al. (2018) · European Journal of Human Genetics · doi:10.1038/s41431-018-0301-5 · Cited by 40
Gibson, C. M., Kernéis, M., Yee, M. K., Daaboul, Y., Korjian, S., Mehr, A. P., Tricoci, P., Alexander, J. H., Kastelein, J. J. P., Mehran, R., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.11.008 · Cited by 39
Self-citationZhou, M., Learned, R. M., Rossi, S. J., Tian, H., DePaoli, A. M., & Ling, L. (2019) · Journal of Lipid Research · doi:10.1194/jlr.m089961 · Cited by 38
Yamashita, S., Arai, H., Bujo, H., Masuda, D., Ohama, T., Ishibashi, T., Yanagi, K., Doi, Y., Nakagawa, S., Yamashiro, K., et al. (2020) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.55327 · Cited by 42
O'Donnell, M. J., McQueen, M., Sniderman, A. D., Paré, G., Wang, X., Hankey, G. J., Rangarajan, S., Chin, S. L., Ps, R., Ferguson, J. P., et al. (2022) · Journal of Stroke · doi:10.5853/jos.2021.02152 · Cited by 45
“However, the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, 55 in which apoA1 was increased by 22% was not associated with a lower risk of stroke, although participants with the largest increases in apoA1 had lower event rates.”
HDL, cholesterol efflux, and ABCA1: Free from good and evil dualism
Ogura, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.07.004 · Cited by 47
HDL Metabolism and Atheroprotection
Maranhão, R. C., & Freitas, F. R. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00001-2 · Cited by 51
Mechanistic Insights to Target Atherosclerosis Residual Risk
Alkhalil, M. (2019) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2019.06.004 · Cited by 39
The mechanistic pathways of oxidative stress in aortic stenosis and clinical implications
Phua, K., Chew, N., Kong, W. K. F., Tan, R., Ye, L., & Poh, K. K. (2022) · Theranostics · doi:10.7150/thno.71813 · Cited by 43
“While CETP inhibition has been found to also significantly lower lipoprotein(a) levels, three large clinical trials investigating the use of CETP inhibitors in cardiovascular disease were terminated early due to toxicity or futility [83-89].”
BackgroundStructure-based mechanism and inhibition of cholesteryl ester transfer protein
Han, X. M., Zhang, M., Liu, J., Wang, J., & Ren, G. (2023) · Current Atherosclerosis Reports · doi:10.1007/s11883-023-01087-1 · Cited by 39
Implications of reverse cholesterol transport: Recent studies
Levinson, S. S., & Wagner, S. G. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.10.018 · Cited by 39
Mantlo, N. B., & Escribano, A. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400574e · Cited by 37
Garattini, S. K., & Bertelè, V. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.07.005 · Cited by 40
“Torcetrapib was also quite active in raising HDL-cholesterol but unfortunately the drug increased mortality [31].”
BackgroundProbucol alleviates atherosclerosis and improves high density lipoprotein function
Zhong, J., Guo, Z., Li, C., Wang, Z.-K., Lai, W., & Tu, Y. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-210 · Cited by 39
“Additionally, the torcetrapib, an inhibitor of potent cholesteryl ester transfer protein (CETP), markedly increased the serum HDL-C levels, but the risk of deaths and cardiac events had been increased simultaneously in patients receiving tocetrapib [4].”
BackgroundThe Effects of Cholesterol Ester Transfer Protein Inhibition on Cholesterol Efflux
Tall, A. R. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.09.018 · Cited by 38
Self-citation
Metadata
- Authors
- Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., Shear, C. L., Revkin, J. H., Buhr, K. A., Fisher, M. R., Tall, A. R., & Brewer, B.
- Affiliations
- The Heart Research Institute (AU)
- St Bartholomew's Hospital (GB)
- Karolinska University Hospital (SE)
- The University of Texas Southwestern Medical Center (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- Hospital Universitario La Paz (ES)
- Columbia University (US)
- Montreal Heart Institute (CA)
- San Francisco General Hospital (US)
- Pfizer (United States) (US)
- University of Wisconsin–Madison (US)
- Columbia University Irving Medical Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-22
- Volume
- 357
- Issue
- 21
- Pages
- 2109-2122
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2048760408
- Cited by
- 3,139
- References
- 15
- Citations by year
- 2026: 74 · 2025: 91 · 2024: 87 · 2023: 91 · 2022: 107 · 2021: 131 · 2020: 104 · 2019: 152 · 2018: 161 · 2017: 203 · 2016: 224 · 2015: 252 · 2014: 204 · 2013: 243 · 2012: 219
- FWCI
- 193.34
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- torcetrapib, cholesteryl ester transfer protein inhibition, cardiovascular events, high cardiovascular risk, atorvastatin, HDL cholesterol, LDL cholesterol, potassium, bicarbonate, aldosterone, mortality, off-target effects, drug safety
- MeSH terms
- Atorvastatin, Aged, Anticholesteremic Agents, Cardiovascular Diseases, Coronary Disease, Double-Blind Method, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, HDL, Cholesterol, LDL, Male, Middle Aged, Mortality, Pyrroles, Quinolines, Cholesterol Ester Transfer Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.